HLB Resubmits Liver Cancer First-Line Treatment to FDA... Rivoceranib Combination Therapy Demonstrates 23.8-Month Overall Survival
HLB is once again pursuing entry into the U.S. market with its liver cancer treatment. As the company challenges for U.S. Food and Drug Administration (FDA) approval on the strength of survival benefits demonstrated in a Phase 3 clinical trial, attention is focused on the upcoming review schedule an

HLB is once again pursuing entry into the U.S. market with its liver cancer treatment. As the company challenges for U.S. Food and Drug Administration (FDA) approval on the strength of survival benefits demonstrated in a Phase 3 clinical trial, attention is focused on the upcoming review schedule and outcome.
■ Rivoceranib-Camrelizumab Combination Resubmitted via NDA and BLA
According to HLB, its U.S. subsidiary Elevar Therapeutics and China's Jiangsu Hengrui Pharmaceuticals resubmitted the New Drug Application (NDA) and Biologics License Application (BLA) for the rivoceranib and camrelizumab combination therapy, being developed as a first-line liver cancer treatment, to the FDA on the 9th (local time).
The resubmission comes in response to deficiencies raised during a previous approval review. The FDA issued a Complete Response Letter (CRL) in July for the application submitted in January of this year, after which Elevar and Hengrui reviewed the relevant matters, consulted with the FDA, and prepared follow-up procedures.
■ Final CARES-310 Analysis... Overall Survival of 23.8 Months, 36% Reduction in Risk of Death
A key point in the approval review is the final analysis of the global Phase 3 CARES-310 trial. The study evaluated the efficacy of the rivoceranib and camrelizumab combination in liver cancer patients who were not eligible for surgical resection or had metastatic disease.
The results showed a median overall survival of 23.8 months in the combination therapy group, 8.6 months longer than the 15.2 months observed in the sorafenib group, the existing standard treatment. The hazard ratio for death was 0.64, meaning the risk of death in the combination therapy group was relatively 36% lower than in the comparator group during the observation period of the clinical trial.
Notably, a median overall survival exceeding 20 months can be regarded as a remarkable clinical achievement in the first-line treatment of liver cancer. However, since patient characteristics and evaluation conditions differ across individual clinical trials, caution is needed when simply comparing these results with those of other treatments to judge superiority.
The final analysis results of CARES-310 were published in the international medical journal The Lancet Oncology. The rivoceranib and camrelizumab combination therapy was also presented as a treatment option in the 2025 Barcelona Clinic Liver Cancer (BCLC) treatment strategy and the European Society for Medical Oncology (ESMO) guidelines.
Kim Dong-geon, CEO of Elevar Therapeutics, emphasized that patients with unresectable liver cancer still need new treatment alternatives. He also stated that with the manufacturing facility inspection process completed, the company would respond to the FDA's approval review based on the demonstrated clinical efficacy.
■ FDA Review Schedule Is Key... Variables Remain Until Final Approval
Going forward, the focus will be on what review schedule the FDA presents after officially accepting the resubmission. Submission of an application is only one step in the approval process and is distinct from final marketing authorization, and the possibility remains that additional review or further requests for supplementary data could arise during the process.
For HLB, the key task is translating the treatment efficacy secured in clinical trials into final approval from the U.S. regulatory authority. Depending on the FDA's decision, the timeline for U.S. commercialization of the new liver cancer drug and the company's future business direction could change.
[This article is intended to convey information on new drug development and approval procedures and does not guarantee FDA approval. Clinical trial results cannot be assumed to lead to final product approval, and review schedules and outcomes may change. The stock prices of related companies may fluctuate depending on approval outcomes and market conditions, and responsibility for investment decisions lies with the investor. AI assistance was used in the writing of this article.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Evernos Holdings (XRPN) Flat at $7.45... Bitcoin at $64,922, Market on Alert Over Weakness in Leading Stock](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F626848%2F4c15339f3668573e%2Fvariants%2Fhero.webp&w=1920&q=75)
